Retatrutide: Weight-Loss Results, Benefits and Side Effects
Retatrutide aka Reta is one of the most closely watched investigational treatments in obesity and metabolic-health research. Unlike existing medications that target one or two hormone receptors, reta activates three: GLP-1, GIP and glucagon.
This triple-receptor mechanism has produced substantial weight loss in clinical trials. In the Phase 3 TRIUMPH-1 trial, participants receiving the highest studied maintenance dose lost an average of 28.3% of their starting body weight after 80 weeks.
However, reta remains an investigational medicine and has not yet been approved for public use. This guide explains what reta is, how it works, its potential benefits, reported side effects and what clinical trials have discovered so far.
Important: This article is for educational purposes only. Retatrutide is not currently approved for general medical use and should not be used outside an authorised clinical trial.
What Is It?
Reta, previously identified as LY3437943, is an investigational once-weekly medication being developed by Eli Lilly.
It is commonly described as a “triple agonist” because a single molecule activates three metabolic hormone receptors:
- Glucagon-like peptide-1 receptor, or GLP-1
- Glucose-dependent insulinotropic polypeptide receptor, or GIP
- Glucagon receptor
These receptors are involved in appetite regulation, blood-glucose control, insulin response and energy metabolism.
Researchers are studying whether targeting all three receptors simultaneously can produce broader metabolic effects than medications that activate GLP-1 alone or both GLP-1 and GIP.
Although it is sometimes called “GLP-3” online, this term is not scientifically accurate. Reta does not target a hormone called GLP-3. “Triple agonist” is the more accurate description.
How Does Retatrutide Work?
Retatrutide combines three different hormone-receptor actions in one molecule.
GLP-1 Receptor Activation
GLP-1 helps regulate appetite, food intake and blood-glucose levels. Activating this receptor may increase feelings of fullness and reduce hunger.
GLP-1 activity can also slow gastric emptying, meaning food may remain in the stomach for longer. This effect may contribute to reduced appetite, although its intensity can change over time.
GIP Receptor Activation
GIP is an incretin hormone released in response to food. It helps regulate insulin secretion and may influence how the body processes nutrients and stores fat.
GIP and GLP-1 receptor activation are also combined in tirzepatide, the active ingredient in Mounjaro and Zepbound.
Glucagon Receptor Activation
Glucagon is normally associated with increasing blood glucose. However, glucagon-receptor activation may also influence energy expenditure and fat metabolism.
Researchers believe that carefully balancing glucagon activity with GLP-1 and GIP activity may contribute to the weight-loss results observed with retatrutide.
The interaction between these three pathways is complex. Further research is required to determine exactly how much each receptor contributes to retatrutide’s overall effects.
Retatrutide Weight-Loss Results
Retatrutide has produced significant weight-loss results in Phase 2 and Phase 3 clinical trials. However, clinical-trial averages should not be interpreted as guaranteed individual results.
Phase 2 Retatrutide Results
A Phase 2 clinical trial published in the New England Journal of Medicine included adults with obesity or overweight and at least one weight-related condition, excluding type 2 diabetes.
At 48 weeks, participants receiving the highest studied dose experienced an average body-weight reduction of approximately 24.2%.
Participants had not clearly reached a weight-loss plateau by the end of the study. This suggested that some participants might have continued losing weight with longer treatment.
These results established reta as a promising investigational treatment but did not prove that it was ready for routine medical use.
Phase 3 TRIUMPH-1 Results
In May 2026, Eli Lilly announced results from TRIUMPH-1, a large Phase 3 clinical trial involving adults with obesity or overweight, at least one weight-related condition and no type 2 diabetes.
At 80 weeks, the reported average weight reductions were:
- Retatrutide 4 mg: 19.0%
- Retatrutide 9 mg: 25.9%
- Retatrutide 12 mg: 28.3%
- Placebo: 2.2%
Participants receiving the 12 mg maintenance dose lost an average of 31.9 kg from an average starting weight of 112.7 kg.
Approximately 45.3% of participants in the 12 mg group achieved at least 30% weight loss.
In a planned extension involving participants who began with a BMI of 35 or higher, average weight reduction reached 30.3% at 104 weeks among those continuing on the 12 mg dose.
These are impressive clinical-trial results, but they do not prove that reta is superior to every existing obesity medication. A direct Phase 3 trial comparing retatrutide with tirzepatide is underway.
Potential Benefits of Retatrutide
Research into reta extends beyond body weight. Potential benefits being investigated include the following.
Reduced Appetite and Food Intake
Activation of GLP-1 and GIP receptors may reduce hunger and improve feelings of fullness after eating. This may help some participants maintain a lower energy intake.
Substantial Body-Weight Reduction
The strongest evidence for reta currently relates to weight management.
Phase 3 results indicate that some participants achieved levels of weight loss historically associated with metabolic surgery. However, this does not make medication equivalent to surgery. These treatments have different benefits, risks and long-term considerations.
Improved Metabolic Markers
TRIUMPH-1 results showed improvements in several cardiometabolic risk markers, including:
- Waist circumference
- Triglycerides
- Non-HDL cholesterol
- Systolic blood pressure
- High-sensitivity C-reactive protein
These findings are encouraging, but improvements in risk markers do not automatically prove that retatrutide prevents heart attacks, strokes or premature death. Dedicated cardiovascular-outcomes research is still needed.
Blood-Glucose Management
Retatrutide is also being investigated as a possible treatment for type 2 diabetes.
Phase 3 findings announced in 2026 reported reductions in HbA1c alongside meaningful weight loss. However, regulatory approval would still be required before it could be prescribed for diabetes.
Obesity-Related Health Conditions
Clinical trials are evaluating reta in several obesity-related conditions, including:
- Obstructive sleep apnoea
- Knee osteoarthritis pain
- Chronic lower-back pain
- Cardiovascular and kidney outcomes
- Metabolic dysfunction-associated steatotic liver disease
Some early Phase 3 findings have shown improvements in knee pain and sleep-apnoea severity. These effects may be partly related to substantial weight loss, although additional metabolic mechanisms are also being investigated.
Retatrutide Side Effects
The most frequently reported retatrutide side effects have involved the gastrointestinal system. Similar effects occur with several medications that activate GLP-1 receptors.
Reported side effects have included:
- Nausea
- Diarrhoea
- Vomiting
- Constipation
- Reduced appetite
- Abdominal discomfort
These effects have generally been more common at higher doses and during dose escalation. Some participants discontinued treatment because of adverse effects.
Phase 2 research also observed dose-dependent increases in heart rate. The clinical importance of this finding requires continued investigation.
Because reta is still being studied, its complete long-term safety profile remains unknown. Rare or delayed risks may only become clear after larger groups have been followed for longer periods.
Retatrutide vs Semaglutide and Tirzepatide
Retatrutide, semaglutide and tirzepatide are different molecules with different receptor profiles.
Semaglutide activates the GLP-1 receptor and is approved for specific type 2 diabetes and weight-management indications.
Tirzepatide activates the GIP and GLP-1 receptors. It is also approved for specific diabetes and weight-management indications.
Retatrutide activates GIP, GLP-1 and glucagon receptors. It remains investigational and is not yet approved.
Separate studies suggest that it may produce greater average weight loss than existing treatments. However, comparisons between different clinical trials should be treated cautiously.
Trials may involve different participants, treatment periods, lifestyle programmes and statistical methods. A direct head-to-head clinical trial provides stronger evidence than comparing results from separate studies.
Is Retatrutide Approved?
As of July 2026, retatrutide is not approved by the FDA or any other regulatory agency. It is not legally available as a public prescription medicine.
Eli Lilly is continuing Phase 3 development across obesity, type 2 diabetes and several obesity-related conditions.
Even strong clinical-trial results do not guarantee approval. Regulatory authorities must review the complete evidence concerning quality, safety, effectiveness and manufacturing.
No confirmed public release date has been announced.
Can You Buy Retatrutide Online?
Products advertised online as “research retatrutide” are not approved prescription medicines. Their identity, concentration, sterility and purity may not have been independently verified.
A label or certificate displayed online does not guarantee that a vial contains the authentic compound. An unregulated product could contain an incorrect concentration, a different substance, contaminants or harmful microorganisms.
Eli Lilly states that legitimate reta is currently available only through authorized clinical trials.
Consumers should be cautious of websites and social-media accounts claiming to sell approved reta for personal use.
Retatrutide Dosage
Retatrutide does not have an approved prescribing dose because it remains investigational.
Clinical trials use study-specific protocols, controlled pharmaceutical formulations and gradual dose-escalation schedules under professional medical monitoring.
Clinical-trial schedules are not personal dosing instructions and should not be copied for unsupervised use.
If retatrutide receives regulatory approval, official prescribing information will define its indications, dose-escalation process, maintenance doses, contraindications and monitoring requirements.
Will Weight Return After Stopping Retatrutide?
Researchers are still establishing what happens after retatrutide treatment is discontinued.
Evidence from other obesity medications suggests that weight regain can occur when treatment ends. This is because the biological factors that influence hunger, fullness and weight gain may return after medication is stopped.
Obesity is a chronic condition. Long-term management may involve nutrition, physical activity, behavioural support, medical monitoring and, where appropriate, ongoing medical treatment.
A dedicated clinical study is investigating how this compound may help maintain weight loss and what happens when participants switch from treatment to a placebo.
Frequently Asked Questions About Retatrutide
What Is Reta Used For?
Reta is being investigated primarily for obesity and type 2 diabetes. Trials are also examining several obesity-related health conditions. It does not currently have an approved medical use.
How Much Weight Can You Lose With Retatrutide?
In the Phase 3 TRIUMPH-1 trial, participants receiving the highest studied maintenance dose lost an average of 28.3% of their starting body weight after 80 weeks.
Individual results varied, and this percentage should not be viewed as a guaranteed outcome.
Is Retatrutide a GLP-1 Medication?
Retatrutide activates the GLP-1 receptor, but it also activates GIP and glucagon receptors. It is therefore more accurately described as a triple-receptor agonist.
Is Retatrutide Stronger Than Tirzepatide?
Results from separate studies suggest that retatrutide may produce greater average weight loss. However, this does not prove that it is more effective or safer than tirzepatide.
A direct clinical trial comparing retatrutide with tirzepatide is underway.
What Are the Most Common Retatrutide Side Effects?
The most common side effects reported in clinical trials have been gastrointestinal. These include nausea, diarrhoea, vomiting and constipation.
The complete long-term safety profile is not yet known.
When Will Retatrutide Become Available?
There is no confirmed release date for reta. Public availability will depend on the completion of clinical trials, regulatory submissions and approval.
Is Retatrutide Available in South Africa?
Reta is not currently an approved public prescription medicine. Products sold privately or online should not be assumed to be authorised, authentic or safe.
Final Thoughts on Retatrutide
Retatrutide is an investigational triple agonist that activates GLP-1, GIP and glucagon receptors.
Phase 3 findings have reported average weight reductions of up to 28.3% at 80 weeks, placing retatrutide among the most promising obesity treatments currently in development.
The results are encouraging, but reta remains unapproved. Important questions about long-term safety, cardiovascular outcomes, weight maintenance and real-world effectiveness still need clear answers.
Until regulatory authorities complete their reviews, it should be regarded as a clinical-trial treatment rather than an approved product for personal use.
GLP-1 Weight Loss Injections: The Ultimate 2026 Guide to Benefits, Side Effects & Results
https://www.ncbi.nlm.nih.gov/search/all/?term=retatrutide
https://www.lilly.com/news/stories/what-to-know-about-retatrutide?
Disclaimer: This article is intended for educational and informational purposes only. Glp1s are research compounds and are not approved in many jurisdictions for the treatment of medical conditions. Research surrounding its efficacy and long-term safety is ongoing.